Donor Selection in the Post-Transplant Cyclophosphamide Era: Do the Little Things Matter?
- 24 April 2026
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501370
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- CT-262: A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell TransplantClinical Lymphoma Myeloma and Leukemia, 2025
- Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTBlood, 2025
- Suboptimal Engraftment and Toxicity after Post-Transplant CyclophosphamideTransplantation and Cellular Therapy, 2025
- Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomesBlood Advances, 2024
- Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantationBlood, 2024
- Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMTBlood, 2024
- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisNew England Journal of Medicine, 2023
- The development of post-transplant cyclophosphamide: Half a century of translational team scienceBlood Reviews, 2022
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2017
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007